pd 153035 has been researched along with canertinib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Das, D; Hong, J | 1 |
| Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
| Breza, N; Keri, G; Orfi, L; Petak, I; Pinter, F; Robert, K; Schwab, R; Varkondi, E | 1 |
2 review(s) available for pd 153035 and canertinib
| Article | Year |
|---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
3 other study(ies) available for pd 153035 and canertinib
| Article | Year |
|---|---|
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2015 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.
Topics: Aminoquinolines; Aniline Compounds; Biological Assay; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Inhibitory Concentration 50; Morpholines; Mutant Proteins; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tyrphostins | 2008 |